Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/29624
Title: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
Authors: Giuseppe Saglio
Dong Wook Kim
Surapol Issaragrisil
Philipp Le Coutre
Gabriel Etienne
Clarisse Lobo
Ricardo Pasquini
Richard E. Clark
Andreas Hochhaus
Timothy P. Hughes
Neil Gallagher
Albert Hoenekopp
Mei Dong
Ariful Haque
Richard A. Larson
Hagop M. Kantarjian
Universita degli Studi di Torino
The Catholic University of Korea
Mahidol University
Charité – Universitätsmedizin Berlin
Institut Bergonie
Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti
Universidade Federal do Parana
Royal Liverpool and Broadgreen University Hospitals NHS Trust
Universitatsklinikum Jena und Medizinische Fakultat
Royal Adelaide Hospital
Novartis International AG
Novartis Pharmaceuticals
University of Chicago
University of Texas MD Anderson Cancer Center
Keywords: Medicine
Issue Date: 17-Jun-2010
Citation: New England Journal of Medicine. Vol.362, No.24 (2010), 2251-2259
Abstract: BACKGROUND: Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase. METHODS: In this phase 3, randomized, open-label, multicenter study, we assigned 846 patients with chronic-phase Philadelphia chromosome-positive CML in a 1:1:1 ratio to receive nilotinib (at a dose of either 300 mg or 400 mg twice daily) or imatinib (at a dose of 400 mg once daily). The primary end point was the rate of major molecular response at 12 months. RESULTS: At 12 months, the rates of major molecular response for nilotinib (44% for the 300-mg dose and 43% for the 400-mg dose) were nearly twice that for imatinib (22%) (P<0.001 for both comparisons). The rates of complete cytogenetic response by 12 months were significantly higher for nilotinib (80% for the 300-mg dose and 78% for the 400-mg dose) than for imatinib (65%) (P<0.001 for both comparisons). Patients receiving either the 300-mg dose or the 400-mg dose of nilotinib twice daily had a significant improvement in the time to progression to the accelerated phase or blast crisis, as compared with those receiving imatinib (P=0.01 and P=0.004, respectively). No patient with progression to the accelerated phase or blast crisis had a major molecular response. Gastrointestinal and fluid-retention events were more frequent among patients receiving imatinib, whereas dermatologic events and headache were more frequent in those receiving nilotinib. Discontinuations due to aminotransferase and bilirubin elevations were low in all three study groups. CONCLUSIONS: Nilotinib at a dose of either 300 mg or 400 mg twice daily was superior to imatinib in patients with newly diagnosed chronic-phase Philadelphia chromosome-positive CML. (ClinicalTrials.gov number, NCT00471497.) Copyright © 2010 Massachusetts Medical Society.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77953691179&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/29624
ISSN: 15334406
00284793
Appears in Collections:Scopus 2006-2010

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.